SNOA News and Press, Sonoma Pharmaceuticals Inc. From 02/16/21

Sonoma Pharmaceuticals (SNOA): FQ3 GAAP EPS of -$0.31.Revenue of $4.94M (+12.3% Y/Y)Shares +0.95% AH.Press Release For further details see: Sonoma Pharmaceuticals reports FQ3 results

Revenues of $4.9 and $16.5 million for the quarter and nine months ended December 31, 2020 increased by 13% and 21%, respectively, compared to the same periods in the prior year due to strong international growth Operating expenses of $2.1 and $7.4 million for the quarter an...

Sonoma Pharmaceuticals (SNOA) and Microderm Technologies announce that their Dermodacyn disinfectant has received import clearance as a medical device for Thailand, and is now available in Hong Kong and Thailand.Dermodacyn disinfecting solution is designed to be spray...

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, disinfectant use and dermatological conditions, and Micr...

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that...

CNS Pharmaceuticals (CNSP) +62%.Cyclo Therapeutics (CYTH) +47%.Mereo BioPharma Group (MREO) +38% on licensing pact with Ultragenyx.DermTech (DMTK) +23% after announcing topline results from its TRUST Study of the company’s non-invasive melanoma rule-out test, the Pigmented Le...

Sonoma Pharmaceuticals (SNOA) +33.7% AH, entered into a non-exclusive distribution agreement with Gabriel Science for the sale of Microcyn Technology products into the dental market and has accepted its first order.Endocyn, a Microcyn Technology product manufactured by Sonoma, is a ...

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that...

Aerpio Pharmaceuticals ARPO -43% after announcing results from Razuprotafib Glaucoma Phase 2 Trial.Greenwich LifeSciences (GLSI) -18%.Gamida Cell (GMDA) -18% on providing regulatory update on biologics license application for Omidubicel.Virgin Galactic Holdings SPCE -...

Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...